Qiagen (QGEN) Competitors

Qiagen (NYSE:QGEN) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, community ranking, media sentiment and profitability.

Which has more volatility and risk, QGEN or BNTX?

Qiagen has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500.

Does the MarketBeat Community prefer QGEN or BNTX?

Qiagen received 109 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 60.29% of users gave Qiagen an outperform vote while only 46.05% of users gave BioNTech an outperform vote.

Company	Underperform	Outperform
Qiagen	Outperform Votes 249 60.29%	Underperform Votes 164 39.71%
BioNTech	Outperform Votes 140 46.05%	Underperform Votes 164 53.95%

Does the media prefer QGEN or BNTX?

In the previous week, Qiagen had 7 more articles in the media than BioNTech. MarketBeat recorded 12 mentions for Qiagen and 5 mentions for BioNTech. BioNTech's average media sentiment score of 1.40 beat Qiagen's score of -0.37 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
BioNTech	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate QGEN or BNTX?

Qiagen currently has a consensus target price of $47.71, indicating a potential upside of 20.73%. BioNTech has a consensus target price of $142.72, indicating a potential upside of 18.92%. Given Qiagen's higher possible upside, research analysts plainly believe Qiagen is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	0 Sell rating(s)	7 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.30
BioNTech	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Do insiders & institutionals have more ownership in QGEN or BNTX?

70.0% of Qiagen shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 9.0% of Qiagen shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Is QGEN or BNTX more profitable?

Qiagen has a net margin of 4.23% compared to BioNTech's net margin of -15.16%. Qiagen's return on equity of 13.92% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	4.23%	13.92%	8.40%
BioNTech	-15.16%	-2.35%	-2.05%

Which has preferable earnings and valuation, QGEN or BNTX?

BioNTech has higher revenue and earnings than Qiagen. BioNTech is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$1.98B	4.43	$83.59M	$0.36	110.03
BioNTech	$3.04B	9.46	$1.01B	-$2.10	-57.15

Summary

Qiagen beats BioNTech on 11 of the 19 factors compared between the two stocks.